Business Wire

HCL and UNLEASH Partner to Develop Solutions for Aquatic Ecosystem Conservation

20.5.2022 18:59:00 EEST | Business Wire | Press release

Share

HCL Group and UNLEASH, a global innovation program for the UN Sustainable Development Goals (SDGs), announced a year-long collaboration to mobilize youth and develop innovative solutions to promote aquatic ecosystem conservation. These solutions will aim to tackle challenges from Source (mountains & glaciers) to Sink (oceans and seas) and their links to terrestrial ecosystems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220520005178/en/

Nature and ocean conservation play a critical role in our survival. Terrestrial and aquatic ecosystems provide us with food, water, oxygen, energy, and medicines. They regulate our climate, provide pollination to crops, and reduce the impact of natural hazards.

Despite the vital importance of our planet’s ecosystems, we are experiencing a human-caused deterioration of our natural habitats: human activity has altered almost 75% of the Earth’s terrestrial surface, squeezing wildlife and nature into an ever-smaller corner.1 Furthermore, ocean heat is at record levels and every year up to 12 million metric tonnes of plastic enter the ocean, damaging ecosystems around the world. Without maintaining healthy and biodiverse terrestrial and aquatic ecosystems, the progress on the remaining United Nations’ SDGs is at critical risk.

To tackle such challenges, UNLEASH and HCL will collaborate to establish a year of youth-led action. Specifically, the partnership will allow youth to develop solutions encompassing SDG 14 (Life below water) and SDG 15 (Life on land), and explore synergies with other SDGs as well. During the process, they will be guided by industry experts and receive hands-on support to ensure that solutions are relatable to the context and feasible in practice.

HCL Group with its large presence in business through HCL Technologies, HCL Infosystems and HCL Healthcare; and its social development organizations including the philanthropic Shiv Nadar Foundation and The Habitats Trust, and its CSR arm – HCL Foundation, has been tackling real on-ground issues related to the SDGs. The Group with its breadth of experience across different sectors and its holistic and powerful sustainability charter is the perfect partner for UNLEASH to successfully push its SDGs innovation efforts.

“Innovation, entrepreneurship, humanity and a people-centric culture are part of HCL’s core, and it is important to us that our progress is reflected in the development of a better world. Our various entities have already been driving important projects to help create a positive impact for the people and the planet. HCL’s collaboration with UNLEASH in bringing innovation to the SDGs, and specifically to the preservation of nature and ocean conservation is an essential step in our overall sustainability efforts”, said Roshni Nadar Malhotra, CEO of HCL, Chairperson of HCL Technologies, Trustee of Shiv Nadar Foundation & Founder of The Habitats Trust.

With HCL’s continuous support on the thematic track From Source to Sink, UNLEASH Talents will have the opportunity to work on localized challenges through joining an UNLEASH Hack at the Shiv Nadar University, Delhi NCR (part of the HCL Group). Earlier this year, UNLEASH Talents participated in three other UNLEASH Hacks related to this theme, exploring challenges of water ecosystems from the Mediterranean, the Danube, Haiti and Hawaii and defining solutions that can drive positive local impact on those regions. The partnership will help scale an existing early-stage solution in the biodiversity space through enrolment in an incubation program, UNLEASH Plus. Thematic insight sessions will be organized throughout 2022, providing inspiration and key learnings on the essence of the theme. These year-long efforts will culminate in the Global Innovation Lab in India that will witness a gathering of 1000+ talented youth for a week long innovation process and help them develop solutions for Indian and global challenges within aquatic and terrestrial ecosystem conservation. The best solutions from the Lab will take home grant prizes to kick-start implementation of the developed solutions. Through the course of this partnership, HCL will enable access to its celebrated business leaders, technical experts, and faculty and academicians of global repute to serve as facilitators, mentors and experts that will help participants across the various programs to develop innovative solutions.

The partnership enables UNLEASH to dive deep into SDG14 and SDG15, and truly establish a community of changemakers, working with nature challenges.

“HCL’s journey in innovation and development is an inspiration for the entire UNLEASH Community. We are very grateful for their partnership on an important matter such as the aquatic conservation of our planet and finding solutions for its preservation through our different programs during the course of this year”, said UNLEASH Chairman Flemming Besenbacher.

About HCL Group

Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies –HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.

The Group also includes one of India’s most prolific philanthropic foundations – the Shiv Nadar Foundation. Established in 1994, the Foundation is committed to the creation of a more equitable, merit-based society by empowering individuals through transformational education. Over the last 27 years, it has invested over US$1billion in seven landmark institutions and initiatives across education and art. The Habitats Trust, also a philanthropic Foundation within the HCL Group, specifically works towards protecting natural habitats and their indigenous species of flora and fauna. Established in 2018, the young foundation is undertaking important initiatives that will help secure a positive future for wild species and their habitats.

HCL Foundation, the Corporate Social Responsibility arm of HCL, has instituted flagship programs and initiatives to contribute towards SDGs. Its work is helping bring about lasting positive impact on the people and planet, through long-term sustainable programs, and ensure equitable access, opportunities, and holistic development for all.

For further information, visit www.hcl.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For any queries or information, please contact:
Sadaf Khan | Sadaf-k@hcl.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye